Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Immune Correlates of Disease Progression in Linked HIV-1 Infection.

Tuen M, Bimela JS, Banin AN, Ding S, Harkins GW, Weiss S, Itri V, Durham AR, Porcella SF, Soni S, Mayr L, Meli J, Torimiro JN, Tongo M, Wang X, Kong XP, Nádas A, Kaufmann DE, Brumme ZL, Nanfack AJ, Quinn TC, Zolla-Pazner S, Redd AD, Finzi A, Gorny MK, Nyambi PN, Duerr R.

Front Immunol. 2019 May 14;10:1062. doi: 10.3389/fimmu.2019.01062. eCollection 2019.

2.

Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.

Liu L, Li L, Nanfack A, Mayr LM, Soni S, Kohutnicki A, Agyingi L, Wang XH, Tuen M, Shao Y, Totrov M, Zolla-Pazner S, Kong XP, Duerr R, Gorny MK.

Virology. 2019 Mar;529:57-64. doi: 10.1016/j.virol.2019.01.011. Epub 2019 Jan 14.

PMID:
30665098
3.

Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection.

Li L, Liu Y, Gorny MK.

Front Immunol. 2018 Nov 26;9:2735. doi: 10.3389/fimmu.2018.02735. eCollection 2018. Review.

4.

Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection.

Chan KW, Pan R, Costa M, Gorny MK, Wang S, Lu S, Kong XP.

J Virol. 2018 Aug 29;92(18). pii: e00641-18. doi: 10.1128/JVI.00641-18. Print 2018 Sep 15.

5.

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.

Cheng HD, Grimm SK, Gilman MS, Gwom LC, Sok D, Sundling C, Donofrio G, Karlsson Hedestam GB, Bonsignori M, Haynes BF, Lahey TP, Maro I, von Reyn CF, Gorny MK, Zolla-Pazner S, Walker BD, Alter G, Burton DR, Robb ML, Krebs SJ, Seaman MS, Bailey-Kellogg C, Ackerman ME.

JCI Insight. 2018 Mar 8;3(5). pii: 97018. doi: 10.1172/jci.insight.97018.

6.

Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.

Nanfack AJ, Redd AD, Bimela JS, Ncham G, Achem E, Banin AN, Kirkpatrick AR, Porcella SF, Agyingi LA, Meli J, Colizzi V, Nádas A, Gorny MK, Nyambi PN, Quinn TC, Duerr R.

J Clin Microbiol. 2017 Sep;55(9):2785-2800. doi: 10.1128/JCM.00634-17. Epub 2017 Jun 28.

7.

Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination.

Balasubramanian P, Kumar R, Williams C, Itri V, Wang S, Lu S, Hessell AJ, Haigwood NL, Sinangil F, Higgins KW, Liu L, Li L, Nyambi P, Gorny MK, Totrov M, Nadas A, Kong XP, Zolla-Pazner S, Hioe CE.

Vaccine. 2017 Mar 7;35(10):1464-1473. doi: 10.1016/j.vaccine.2016.11.107. Epub 2017 Feb 6.

8.

Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.

Musich T, Li L, Liu L, Zolla-Pazner S, Robert-Guroff M, Gorny MK.

J Virol. 2017 Mar 29;91(8). pii: e02325-16. doi: 10.1128/JVI.02325-16. Print 2017 Apr 15.

9.

Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus.

Reed JH, Gorny MK, Li L, Cardozo T, Buyon JP, Clancy RM.

J Autoimmun. 2017 May;79:99-104. doi: 10.1016/j.jaut.2017.01.004. Epub 2017 Jan 22.

10.

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Costa MR, Pollara J, Edwards RW, Seaman MS, Gorny MK, Montefiori DC, Liao HX, Ferrari G, Lu S, Wang S.

J Virol. 2016 Oct 28;90(22):10362-10378. doi: 10.1128/JVI.01458-16. Print 2016 Nov 15.

11.

Combination of Antiretroviral Drugs and Radioimmunotherapy Specifically Kills Infected Cells from HIV-Infected Individuals.

Tsukrov D, McFarren A, Morgenstern A, Bruchertseifer F, Dolce E, Gorny MK, Zolla-Pazner S, Berman JW, Schoenbaum E, Zingman BS, Casadevall A, Dadachova E.

Front Med (Lausanne). 2016 Sep 26;3:41. eCollection 2016.

12.

Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.

Hessell AJ, McBurney S, Pandey S, Sutton W, Liu L, Li L, Totrov M, Zolla-Pazner S, Haigwood NL, Gorny MK.

Vaccine. 2016 May 23;34(24):2713-21. doi: 10.1016/j.vaccine.2016.04.027. Epub 2016 Apr 19.

13.

A fully human antibody to gp41 selectively eliminates HIV-infected cells that transmigrated across a model human blood brain barrier.

McFarren A, Lopez L, Williams DW, Veenstra M, Bryan RA, Goldsmith A, Morgenstern A, Bruchertseifer F, Zolla-Pazner S, Gorny MK, Eugenin EA, Berman JW, Dadachova E.

AIDS. 2016 Feb 20;30(4):563-72. doi: 10.1097/QAD.0000000000000968.

14.

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF.

Cell Host Microbe. 2015 Sep 9;18(3):354-62. doi: 10.1016/j.chom.2015.08.006.

15.

Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Kumar R, Pan R, Upadhyay C, Mayr L, Cohen S, Wang XH, Balasubramanian P, Nádas A, Seaman MS, Zolla-Pazner S, Gorny MK, Kong XP, Hioe CE.

J Virol. 2015 Sep;89(17):9090-102. doi: 10.1128/JVI.01280-15. Epub 2015 Jun 24.

16.

The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.

Pan R, Gorny MK, Zolla-Pazner S, Kong XP.

J Virol. 2015 Aug;89(15):8003-10. doi: 10.1128/JVI.00754-15. Epub 2015 May 27.

17.

A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.

Li L, Wang XH, Williams C, Volsky B, Steczko O, Seaman MS, Luthra K, Nyambi P, Nadas A, Giudicelli V, Lefranc MP, Zolla-Pazner S, Gorny MK.

Mol Immunol. 2015 Aug;66(2):364-74. doi: 10.1016/j.molimm.2015.04.011. Epub 2015 May 18.

18.

Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.

Upadhyay C, Mayr LM, Zhang J, Kumar R, Gorny MK, Nádas A, Zolla-Pazner S, Hioe CE.

J Virol. 2014 Nov;88(21):12853-65. doi: 10.1128/JVI.02125-14. Epub 2014 Aug 27.

19.

Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.

Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, Bailey-Kellogg C, Ackerman ME, Scanlan C, Zolla-Pazner S, Alter G.

AIDS. 2014 Nov 13;28(17):2523-30. doi: 10.1097/QAD.0000000000000444.

20.

Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV.

Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP.

J Virol. 2014 Apr;88(8):4100-12. doi: 10.1128/JVI.03153-13. Epub 2014 Jan 29.

21.

Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.

deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, Gottardo R, Edlefsen P, Self S, Tang H, Greene K, Gao H, Daniell X, Sarzotti-Kelsoe M, Gorny MK, Zolla-Pazner S, LaBranche CC, Mascola JR, Korber BT, Montefiori DC.

J Virol. 2014 Mar;88(5):2489-507. doi: 10.1128/JVI.02853-13. Epub 2013 Dec 18.

22.

Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

Salomon A, Krachmarov C, Lai Z, Honnen W, Zingman BS, Sarlo J, Gorny MK, Zolla-Pazner S, Robinson JE, Pinter A.

Virology. 2014 Jan 5;448:363-74. doi: 10.1016/j.virol.2013.10.007. Epub 2013 Nov 12.

23.

Thermodynamic signatures of the antigen binding site of mAb 447-52D targeting the third variable region of HIV-1 gp120.

Killikelly A, Zhang HT, Spurrier B, Williams C, Gorny MK, Zolla-Pazner S, Kong XP.

Biochemistry. 2013 Sep 10;52(36):6249-57. doi: 10.1021/bi400645e. Epub 2013 Aug 23.

24.

Cross-neutralizing activity of human anti-V3 monoclonal antibodies derived from non-B clade HIV-1 infected individuals.

Andrabi R, Williams C, Wang XH, Li L, Choudhary AK, Wig N, Biswas A, Luthra K, Nadas A, Seaman MS, Nyambi P, Zolla-Pazner S, Gorny MK.

Virology. 2013 May 10;439(2):81-8. doi: 10.1016/j.virol.2012.12.010. Epub 2013 Mar 5.

25.

Different pattern of immunoglobulin gene usage by HIV-1 compared to non-HIV-1 antibodies derived from the same infected subject.

Li L, Wang XH, Banerjee S, Volsky B, Williams C, Virland D, Nadas A, Seaman MS, Chen X, Spearman P, Zolla-Pazner S, Gorny MK.

PLoS One. 2012;7(6):e39534. doi: 10.1371/journal.pone.0039534. Epub 2012 Jun 25.

26.

Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication.

Dadachova E, Kitchen SG, Bristol G, Baldwin GC, Revskaya E, Empig C, Thornton GB, Gorny MK, Zolla-Pazner S, Casadevall A.

PLoS One. 2012;7(3):e31866. doi: 10.1371/journal.pone.0031866. Epub 2012 Mar 9. Erratum in: PLoS One. 2012;7(8): doi/10.1371/annotation/c4cb1c2c-a436-4f7a-ada9-1feb42aebca1.

27.

Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Gorny MK, Pan R, Williams C, Wang XH, Volsky B, O'Neal T, Spurrier B, Sampson JM, Li L, Seaman MS, Kong XP, Zolla-Pazner S.

Virology. 2012 Jun 5;427(2):198-207. doi: 10.1016/j.virol.2012.02.003. Epub 2012 Mar 7.

28.

Clonal analysis of human anti-V3 monoclonal antibodies selected by a V3 tetramer.

Li L, Wang XH, Banerjee S, Volsky B, Williams C, Moody MA, Zolla-Pazner S, Gorny MK.

Hum Antibodies. 2012;21(3-4):65-73. doi: 10.3233/HAB-130264.

29.

Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51/VL lambda genes define a conserved antigenic structure.

Gorny MK, Sampson J, Li H, Jiang X, Totrov M, Wang XH, Williams C, O'Neal T, Volsky B, Li L, Cardozo T, Nyambi P, Zolla-Pazner S, Kong XP.

PLoS One. 2011;6(12):e27780. doi: 10.1371/journal.pone.0027780. Epub 2011 Dec 2.

30.

Characterization of structural features and diversity of variable-region determinants of related quaternary epitopes recognized by human and rhesus macaque monoclonal antibodies possessing unusually potent neutralizing activities.

Krachmarov C, Lai Z, Honnen WJ, Salomon A, Gorny MK, Zolla-Pazner S, Robinson J, Pinter A.

J Virol. 2011 Oct;85(20):10730-40. doi: 10.1128/JVI.00365-11. Epub 2011 Aug 10.

31.

Structural analysis of human and macaque mAbs 2909 and 2.5B: implications for the configuration of the quaternary neutralizing epitope of HIV-1 gp120.

Spurrier B, Sampson JM, Totrov M, Li H, O'Neal T, Williams C, Robinson J, Gorny MK, Zolla-Pazner S, Kong XP.

Structure. 2011 May 11;19(5):691-9. doi: 10.1016/j.str.2011.02.012.

32.

Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P.

PLoS One. 2011 Feb 23;6(2):e17253. doi: 10.1371/journal.pone.0017253.

33.

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies.

Wu X, Changela A, O'Dell S, Schmidt SD, Pancera M, Yang Y, Zhang B, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Kwong PD, Mascola JR.

J Virol. 2011 May;85(9):4578-85. doi: 10.1128/JVI.02585-10. Epub 2011 Feb 16.

34.

Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Changela A, Wu X, Yang Y, Zhang B, Zhu J, Nardone GA, O'Dell S, Pancera M, Gorny MK, Phogat S, Robinson JE, Stamatatos L, Zolla-Pazner S, Mascola JR, Kwong PD.

J Virol. 2011 Mar;85(6):2524-35. doi: 10.1128/JVI.02335-10. Epub 2010 Dec 29.

35.

Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens.

Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, Xia SM, Liao HX, Gorny MK, Zolla-Pazner S, Haynes BF, Alam SM.

J Virol. 2011 Feb;85(3):1340-7. doi: 10.1128/JVI.01680-10. Epub 2010 Nov 24.

36.

Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffold.

Totrov M, Jiang X, Kong XP, Cohen S, Krachmarov C, Salomon A, Williams C, Seaman MS, Abagyan R, Cardozo T, Gorny MK, Wang S, Lu S, Pinter A, Zolla-Pazner S.

Virology. 2010 Sep 30;405(2):513-23. doi: 10.1016/j.virol.2010.06.027. Epub 2010 Jul 21. Erratum in: Virology. 2011 Jan 20;409(2):360. Abagyan, Ruben [added].

37.

Conserved structural elements in the V3 crown of HIV-1 gp120.

Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP.

Nat Struct Mol Biol. 2010 Aug;17(8):955-61. doi: 10.1038/nsmb.1861. Epub 2010 Jul 11.

PMID:
20622876
38.

Characterization of a discontinuous epitope of the HIV envelope protein gp120 recognized by a human monoclonal antibody using chemical modification and mass spectrometric analysis.

Hager-Braun C, Hochleitner EO, Gorny MK, Zolla-Pazner S, Bienstock RJ, Tomer KB.

J Am Soc Mass Spectrom. 2010 Oct;21(10):1687-98. doi: 10.1016/j.jasms.2010.03.031. Epub 2010 Mar 31.

39.

Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.

Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S.

PLoS One. 2010 Apr 21;5(4):e10254. doi: 10.1371/journal.pone.0010254.

40.

Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.

Robinson JE, Franco K, Elliott DH, Maher MJ, Reyna A, Montefiori DC, Zolla-Pazner S, Gorny MK, Kraft Z, Stamatatos L.

J Virol. 2010 Apr;84(7):3443-53. doi: 10.1128/JVI.02617-09. Epub 2010 Jan 27.

41.

Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.

Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zolla-Pazner S, Kong XP.

Structure. 2009 Nov 11;17(11):1538-46. doi: 10.1016/j.str.2009.09.012.

42.

Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins.

Kimura T, Wang XH, Williams C, Zolla-Pazner S, Gorny MK.

Hum Antibodies. 2009;18(1-2):35-40. doi: 10.3233/HAB-2009-0200.

43.

Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies.

Yuan W, Li X, Kasterka M, Gorny MK, Zolla-Pazner S, Sodroski J.

AIDS Res Hum Retroviruses. 2009 Mar;25(3):319-28. doi: 10.1089/aid.2008.0213.

44.

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A.

Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25.

45.

Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set.

Dhillon AK, Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson IA.

Acta Crystallogr D Biol Crystallogr. 2008 Jul;D64(Pt 7):792-802. doi: 10.1107/S0907444908013978. Epub 2008 Jun 18.

46.

In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120.

Visciano ML, Tuen M, Gorny MK, Hioe CE.

Virology. 2008 Mar 15;372(2):409-20. Epub 2007 Dec 4.

47.

Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection.

Alam SM, Scearce RM, Parks RJ, Plonk K, Plonk SG, Sutherland LL, Gorny MK, Zolla-Pazner S, Vanleeuwen S, Moody MA, Xia SM, Montefiori DC, Tomaras GD, Weinhold KJ, Karim SA, Hicks CB, Liao HX, Robinson J, Shaw GM, Haynes BF.

J Virol. 2008 Jan;82(1):115-25. Epub 2007 Oct 17.

49.

Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H.

PLoS Med. 2006 Nov;3(11):e427.

50.

Immunoprophylaxis against mother-to-child transmission of HIV-1.

Gorny MK, Zolla-Pazner S.

PLoS Med. 2006 Jul;3(7):e259. Epub 2006 Jul 18. No abstract available.

Supplemental Content

Loading ...
Support Center